Strides Pharma Science has informed that it has attached Press Release on 19th March 2021 issued by Stelis Biopharma, the biopharmaceutical division of Strides titled ‘Stelis concludes US$ 195m Series B and Series C fund raise Significant interest from marquee long term investors’.
The above information is a part of company’s filings submitted to BSE.